For children born with a damaged or missing pulmonary valve, growing up has meant growing out of their own heart repair. A valve implanted in a toddler can become too small within years, requiring a return to the operating room for some patients. The FDA approved a device on October 1, 2026, that aims to address that problem: the AUTUS Size-Adjustable Valve, the first heart valve designed to be expanded inside a child’s body after implantation.
How the Valve Works
The AUTUS valve starts small and can expand as a child grows, potentially reducing the need for repeat surgical replacements.
Surgeons implant AUTUS at approximately 13 millimeters in diameter, a size intended for younger pediatric patients whose anatomy and clinical assessment make them suitable candidates. The pulmonary valve controls blood flow from the right ventricle to the lungs; when it is diseased or absent at birth, surgical replacement may be required.
As the child grows, physicians can expand the valve using a balloon catheter, a thin tube fitted with an inflatable balloon. The valve can reach approximately 22 millimeters, comparable to the size of an adult pulmonary valve.
The FDA also identifies AUTUS as the first U.S.-approved heart valve to use synthetic polymeric leaflets. These flexible flaps open and close to regulate blood flow, replacing animal-derived tissue used in conventional valves.
What the Clinical Study Showed
The FDA based its approval on a 62-patient study, with early results showing a clean safety record and functional valve performance.
The FDA based its approval on a pivotal study conducted across 12 U.S. sites, enrolling 62 pediatric patients. Here is what that study reported:
- All patients had a successful implantation procedure.
- At six months, 60 evaluated patients showed acceptable blood flow and no more than mild pulmonary regurgitation, meaning backward leakage through the pulmonary valve.
- No deaths, strokes, or treatment-requiring blood clots were recorded during the reported follow-up period.
- Three patients experienced a fracture in the valve frame; two had reduced movement of one leaflet. None of those events caused symptoms, according to the FDA.
- Two patients whose valves began to underperform as they grew had them successfully expanded without invasive surgery, though the FDA noted this experience remains limited.
Edwards Lifesciences reported the study met its primary safety and effectiveness endpoints.
What the Evidence Does and Does Not Prove
Early data are encouraging, but the study is small and the follow-up period is too short to confirm long-term durability.
One-year follow-up data support the early durability of the polymeric leaflets. That timeline is too short to confirm how the valve will perform across a child’s full growth into adulthood.
The current data do not establish how many repeat surgeries AUTUS will ultimately prevent compared with existing valves. Open questions include how often the valve will require balloon expansion and whether expansion remains safe across different anatomies. Whether some patients will still need later interventions is also unresolved.
AUTUS is approved for selected pediatric patients with congenital pulmonary valve disease. It is not indicated for every child with congenital heart disease.
The FDA reviewed AUTUS through its premarket approval pathway, which the agency describes as its most rigorous review process for higher-risk medical devices. The device previously received Breakthrough Device designation, according to the FDA and secondary reporting.
For families navigating congenital heart disease, the approval means a new option now exists with full regulatory backing. A planned 10-year follow-up period, according to Edwards, will provide the longer-term evidence needed to confirm the valve’s durability and its impact on repeat surgery rates.
